Alexei Gorelik
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Alexei Gorelik has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
- Bhushan Nagar
Department of Biochemistry, McGill University, Montreal, Quebec, Canada
16 shared publications Katalin Illes
Department of Biochemistry, McGill University, Montreal, Quebec, Canada
16 shared publicationsAhmad Gebai
Department of Biochemistry and Groupe de Recherche Axé sur la Structure des Protéines, McGill University, Montreal, QC H3G 0B1, Canada
3 shared publicationsGiulio Superti-Furga
The CeMM Research Center for Molecular Medicine, Austrian Academy of Sciences, 1090 Vienna, Austria, and
3 shared publicationsAntsa Randriamihaja
Department of Biochemistry and Groupe de Recherche Axé sur la Structure des Protéines, McGill University, Montreal, Quebec, Canada
2 shared publicationsBhushan Nagar
Department of Biochemistry, McGill University, Quebec, Canada
2 shared publications
Latest Publications
- Open Access
- 19 May 2023
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 9 (20) , eadf8169
Structure of the immunoregulatory sialidase NEU1
Sialic acids linked to glycoproteins and glycolipids are important mediators of cell and protein recognition events. These sugar residues are removed by neuraminidases (sialidases). Neuraminidase-1 (sialidase-1 or NEU1) is a ubiquitously expressed mammalian sialidase located in lysosomes and on the cell membrane. Because of its modulation of multiple signaling processes, it is a potential therapeutic target for cancers and immune disorders. Genetic defects in NEU1 or in its protective protein cathepsin A (PPCA, CTSA) cause the lysosomal storage diseases sialidosis and galactosialidosis. To further our understanding of this enzyme’s function at the molecular level, we determined the three-dimensional structure of murine NEU1. The enzyme oligomerizes through two self-association interfaces and displays a wide substrate-binding cavity. A catalytic loop adopts an inactive conformation. We propose a mechanism of activation involving a conformational change in this loop upon binding to its protective protein. These findings may facilitate the development of selective inhibitor and agonist therapies.
- 19 May 2023
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 9 (20) , eadf8169
Open AccessStructure of the immunoregulatory sialidase NEU1
Sialic acids linked to glycoproteins and glycolipids are important mediators of cell and protein recognition events. These sugar residues are removed by neuraminidases (sialidases). Neuraminidase-1 (sialidase-1 or NEU1) is a ubiquitously expressed mammalian sialidase located in lysosomes and on the cell membrane. Because of its modulation of multiple signaling processes, it is a potential therapeutic target for cancers and immune disorders. Genetic defects in NEU1 or in its protective protein cathepsin A (PPCA, CTSA) cause the lysosomal storage diseases sialidosis and galactosialidosis. To further our understanding of this enzyme’s function at the molecular level, we determined the three-dimensional structure of murine NEU1. The enzyme oligomerizes through two self-association interfaces and displays a wide substrate-binding cavity. A catalytic loop adopts an inactive conformation. We propose a mechanism of activation involving a conformational change in this loop upon binding to its protective protein. These findings may facilitate the development of selective inhibitor and agonist therapies.
- Open Access
- 8 August 2022
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 119 (33)
Structures of the mannose-6-phosphate pathway enzyme, GlcNAc-1-phosphotransferase
The mannose-6-phosphate (M6P) pathway is responsible for the transport of hydrolytic enzymes to lysosomes. N-acetylglucosamine-1-phosphotransferase (GNPT) catalyzes the first step of tagging these hydrolases with M6P, which when recognized by receptors in the Golgi diverts them to lysosomes. Genetic defects in the GNPT subunits, GNPTAB and GNPTG, cause the lysosomal storage diseases mucolipidosis types II and III. To better understand its function, we determined partial three-dimensional structures of the GNPT complex. The catalytic domain contains a deep cavity for binding of uridine diphosphate- N -acetylglucosamine, and the surrounding residues point to a one-step transfer mechanism. An isolated structure of the gamma subunit of GNPT reveals that it can bind to mannose-containing glycans in different configurations, suggesting that it may play a role in directing glycans into the active site. These findings may facilitate the development of therapies for lysosomal storage diseases.
- 8 August 2022
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 119 (33)
Open AccessStructures of the mannose-6-phosphate pathway enzyme, GlcNAc-1-phosphotransferase
The mannose-6-phosphate (M6P) pathway is responsible for the transport of hydrolytic enzymes to lysosomes. N-acetylglucosamine-1-phosphotransferase (GNPT) catalyzes the first step of tagging these hydrolases with M6P, which when recognized by receptors in the Golgi diverts them to lysosomes. Genetic defects in the GNPT subunits, GNPTAB and GNPTG, cause the lysosomal storage diseases mucolipidosis types II and III. To better understand its function, we determined partial three-dimensional structures of the GNPT complex. The catalytic domain contains a deep cavity for binding of uridine diphosphate- N -acetylglucosamine, and the surrounding residues point to a one-step transfer mechanism. An isolated structure of the gamma subunit of GNPT reveals that it can bind to mannose-containing glycans in different configurations, suggesting that it may play a role in directing glycans into the active site. These findings may facilitate the development of therapies for lysosomal storage diseases.
- Open Access
- 14 May 2021
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 7 (20) , eabf4155
Structure of the murine lysosomal multienzyme complex core
The 3D structure of the complex formed by the enzymes GLB1 and CTSA furthers our understanding of lysosomal storage diseases.
- 14 May 2021
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 7 (20) , eabf4155
Open AccessStructure of the murine lysosomal multienzyme complex core
The 3D structure of the complex formed by the enzymes GLB1 and CTSA furthers our understanding of lysosomal storage diseases.
- 6 August 2020
- Published by Wiley in Protein Science
- Vol. 29 (10) , 2054-2061
Crystal structure of the nucleotide‐metabolizing enzyme NTPDase4
The ecto‐nucleoside triphosphate diphosphohydrolases (NTPDases) are a family of enzymes found on the cell surface and in the lumen of certain organelles, that are major regulators of purinergic signaling. Their intracellular roles, however, have not been clearly defined. NTPDase4 (UDPase, ENTPD4) is a Golgi protein potentially involved in nucleotide recycling as part of protein glycosylation, and is also found in lysosomes, where its purpose is unknown. To further our understanding of NTPDase4 function, we determined its crystal structure. The enzyme adopts a wide open, inactive conformation. Differences in the nucleotide‐binding site relative to its homologs could account for its substrate selectivity. The putative membrane‐interacting loop of cell‐surface NTPDases is drastically altered in NTPDase4, potentially affecting its interdomain dynamics at the Golgi membrane.
- 6 August 2020
- Published by Wiley in Protein Science
- Vol. 29 (10) , 2054-2061
Crystal structure of the nucleotide‐metabolizing enzyme NTPDase4
The ecto‐nucleoside triphosphate diphosphohydrolases (NTPDases) are a family of enzymes found on the cell surface and in the lumen of certain organelles, that are major regulators of purinergic signaling. Their intracellular roles, however, have not been clearly defined. NTPDase4 (UDPase, ENTPD4) is a Golgi protein potentially involved in nucleotide recycling as part of protein glycosylation, and is also found in lysosomes, where its purpose is unknown. To further our understanding of NTPDase4 function, we determined its crystal structure. The enzyme adopts a wide open, inactive conformation. Differences in the nucleotide‐binding site relative to its homologs could account for its substrate selectivity. The putative membrane‐interacting loop of cell‐surface NTPDases is drastically altered in NTPDase4, potentially affecting its interdomain dynamics at the Golgi membrane.
- Open Access
- 2 April 2019
- Published by Springer Nature in Scientific Reports
- Vol. 9 (1) , 1-19
Identification of Allosteric Inhibitors against Active Caspase-6
Caspase-6 is a cysteine protease that plays essential roles in programmed cell death, axonal degeneration, and development. The excess neuronal activity of Caspase-6 is associated with Alzheimer disease neuropathology and age-dependent cognitive impairment. Caspase-6 inhibition is a promising strategy to stop early stage neurodegenerative events, yet finding potent and selective Caspase-6 inhibitors has been a challenging task due to the overlapping structural and functional similarities between caspase family members. Here, we investigated how four rare non-synonymous missense single-nucleotide polymorphisms (SNPs), resulting in amino acid substitutions outside human Caspase-6 active site, affect enzyme structure and catalytic efficiency. Three investigated SNPs were found to align with a putative allosteric pocket with low sequence conservation among human caspases. Virtual screening of 57,700 compounds against the putative Caspase-6 allosteric pocket, followed byin vitrotesting of the best virtual hits in recombinant human Caspase-6 activity assays identified novel allosteric Caspase-6 inhibitors with IC50andKivalues ranging from ~2 to 13 µM. This report may pave the way towards the development and optimisation of novel small molecule allosteric Caspase-6 inhibitors and illustrates that functional characterisation of rare natural variants holds promise for the identification of allosteric sites on other therapeutic targets in drug discovery.
- 2 April 2019
- Published by Springer Nature in Scientific Reports
- Vol. 9 (1) , 1-19
Open AccessIdentification of Allosteric Inhibitors against Active Caspase-6
Caspase-6 is a cysteine protease that plays essential roles in programmed cell death, axonal degeneration, and development. The excess neuronal activity of Caspase-6 is associated with Alzheimer disease neuropathology and age-dependent cognitive impairment. Caspase-6 inhibition is a promising strategy to stop early stage neurodegenerative events, yet finding potent and selective Caspase-6 inhibitors has been a challenging task due to the overlapping structural and functional similarities between caspase family members. Here, we investigated how four rare non-synonymous missense single-nucleotide polymorphisms (SNPs), resulting in amino acid substitutions outside human Caspase-6 active site, affect enzyme structure and catalytic efficiency. Three investigated SNPs were found to align with a putative allosteric pocket with low sequence conservation among human caspases. Virtual screening of 57,700 compounds against the putative Caspase-6 allosteric pocket, followed byin vitrotesting of the best virtual hits in recombinant human Caspase-6 activity assays identified novel allosteric Caspase-6 inhibitors with IC50andKivalues ranging from ~2 to 13 µM. This report may pave the way towards the development and optimisation of novel small molecule allosteric Caspase-6 inhibitors and illustrates that functional characterisation of rare natural variants holds promise for the identification of allosteric sites on other therapeutic targets in drug discovery.
- Open Access
- 15 December 2018
- Published by Wiley in The FEBS Journal
- Vol. 286 (7) , 1319-1331
The structure of mammalian β‐mannosidase provides insight into β‐mannosidosis and nystagmus
β‐Mannosidase is a lysosomal enzyme from the glycosyl hydrolase family 2 that cleaves the single β(1–4)‐linked mannose at the nonreducing end of N‐glycosylated proteins, and plays an important role in the polysaccharide degradation pathway. Mutations in the MANBA gene, which encodes the β‐mannosidase, can lead to the lysosomal storage disease β‐mannosidosis, as well as nystagmus, an eye condition characterized by involuntary eye movements. Here, we present the first structures of a mammalian β‐mannosidase in both the apo‐ and mannose‐bound forms. The structure is similar to previously determined β‐mannosidase structures with regard to domain organization and fold, however, there are important differences that underlie substrate specificity between species. Additionally, in contrast to most other ligand‐bound β‐mannosidases from bacterial and fungal sources where bound sugars were in a boat‐like conformation, we find the mannose in the chair conformation. Evaluation of known disease mutations in the MANBA gene provides insight into their impact on disease phenotypes. Together, these results will be important for the design of therapeutics for treating diseases caused by β‐mannosidase deficiency.Database: Structural data are available in the Protein Data Bank under the accession numbers 6DDT and 6DDU.
- 15 December 2018
- Published by Wiley in The FEBS Journal
- Vol. 286 (7) , 1319-1331
Open AccessThe structure of mammalian β‐mannosidase provides insight into β‐mannosidosis and nystagmus
β‐Mannosidase is a lysosomal enzyme from the glycosyl hydrolase family 2 that cleaves the single β(1–4)‐linked mannose at the nonreducing end of N‐glycosylated proteins, and plays an important role in the polysaccharide degradation pathway. Mutations in the MANBA gene, which encodes the β‐mannosidase, can lead to the lysosomal storage disease β‐mannosidosis, as well as nystagmus, an eye condition characterized by involuntary eye movements. Here, we present the first structures of a mammalian β‐mannosidase in both the apo‐ and mannose‐bound forms. The structure is similar to previously determined β‐mannosidase structures with regard to domain organization and fold, however, there are important differences that underlie substrate specificity between species. Additionally, in contrast to most other ligand‐bound β‐mannosidases from bacterial and fungal sources where bound sugars were in a boat‐like conformation, we find the mannose in the chair conformation. Evaluation of known disease mutations in the MANBA gene provides insight into their impact on disease phenotypes. Together, these results will be important for the design of therapeutics for treating diseases caused by β‐mannosidase deficiency.Database: Structural data are available in the Protein Data Bank under the accession numbers 6DDT and 6DDU.
- 7 December 2018
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 62 (2) , 987-992
Molecular Mechanism of Inhibition of Acid Ceramidase by Carmofur
Human acid ceramidase (AC) is a lysosomal cysteine amidase, which has received a great deal of interest in recent years as a potential target for the development of new therapeutics against melanoma and glioblastoma tumors. Despite the strong interest in obtaining structural information, only the structures of the apo-AC enzyme in its zymogen and activated conformations are available. In this work, the crystal structure of AC in complex with the covalent carmofur inhibitor is presented. Carmofur is an antineoplastic drug containing an electrophilic carbonyl reactive group that targets the catalytic cysteine. This novel structural data explains the basis of the AC inhibition, provides insights into the enzymatic properties of the protein, and is a great aid toward the structure-based drug design of potent inhibitors for AC, providing the detailed mechanism, which has eluded the scientific community for more than 30 years, of carmofur’s mysterious 5-fluorouracil-independent anti-tumor activity.
- 7 December 2018
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 62 (2) , 987-992
Molecular Mechanism of Inhibition of Acid Ceramidase by Carmofur
Human acid ceramidase (AC) is a lysosomal cysteine amidase, which has received a great deal of interest in recent years as a potential target for the development of new therapeutics against melanoma and glioblastoma tumors. Despite the strong interest in obtaining structural information, only the structures of the apo-AC enzyme in its zymogen and activated conformations are available. In this work, the crystal structure of AC in complex with the covalent carmofur inhibitor is presented. Carmofur is an antineoplastic drug containing an electrophilic carbonyl reactive group that targets the catalytic cysteine. This novel structural data explains the basis of the AC inhibition, provides insights into the enzymatic properties of the protein, and is a great aid toward the structure-based drug design of potent inhibitors for AC, providing the detailed mechanism, which has eluded the scientific community for more than 30 years, of carmofur’s mysterious 5-fluorouracil-independent anti-tumor activity.
- 1 November 2018
- Published by Elsevier in Journal of Structural Biology
- Vol. 204 (2) , 145-150
Crystal structure of saposin D in an open conformation
- 1 November 2018
- Published by Elsevier in Journal of Structural Biology
- Vol. 204 (2) , 145-150
Crystal structure of saposin D in an open conformation
- 9 October 2018
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 115 (43) , 201811759-E10040
Molecular mechanism of activation of the immunoregulatory amidase NAAA
Significance: There is a strong need for new analgesic and antiinflammatory medicines that are both effective and safe. Animal studies have shown that inhibition of N -acylethanolamine acid amidase (NAAA)—an intracellular enzyme that degrades the lipid mediator palmitoylethanolamide—causes profound analgesic and antiinflammatory effects. To facilitate the discovery of drugs targeting this protein and to better understand its mechanism of action, we determined its 3D structure. Our results illustrate the sequential steps leading to the activation of NAAA at lipid membranes, and reveal how current inhibitors block this enzyme.
- 9 October 2018
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 115 (43) , 201811759-E10040
Molecular mechanism of activation of the immunoregulatory amidase NAAA
Significance: There is a strong need for new analgesic and antiinflammatory medicines that are both effective and safe. Animal studies have shown that inhibition of N -acylethanolamine acid amidase (NAAA)—an intracellular enzyme that degrades the lipid mediator palmitoylethanolamide—causes profound analgesic and antiinflammatory effects. To facilitate the discovery of drugs targeting this protein and to better understand its mechanism of action, we determined its 3D structure. Our results illustrate the sequential steps leading to the activation of NAAA at lipid membranes, and reveal how current inhibitors block this enzyme.